Dr. Lai-Goldman is the Chief Executive Officer and President of GeneCentric Therapeutics. She is also a founder and director of the Company. Dr. Lai-Goldman spent more than 18 years at Laboratory Corporation of America, Holdings (LabCorp), the last 10 years as Executive Vice President, Chief Medical Officer and Chief Scientific Officer. She served on LabCorp’s Executive and Management Committees, with strategic and operations responsibilities for 3 major genomic laboratories comprising more than 700 people. During her tenure at the Company, she led all clinical, scientific and medical activities, including the introduction of more than 400 clinical assays. Her experience includes the development of partnerships, licensing, and acquisitions. After leaving LabCorp, Dr. Lai-Goldman became a Venture Partner at Hatteras Venture Partners and is the managing partner of Personalized Science, LLC, a consulting company founded to assist customers achieve successful adoption of innovative diagnostics. Dr. Lai-Goldman received her BS from the University of Pennsylvania and MD from Columbia University College of Physicians and Surgeons. Dr. Lai-Goldman is Board-certified in anatomic and clinical pathology.

Mr. Walter Capone is Chief Business Officer of GeneCentric Therapeutics. He most recently served as CEO and President of the Multiple Myeloma Research Foundation (MMRF) and the Multiple Myeloma Research Consortium (MMRC), advancing industry, academic research, government agency and patient community collaborations to drive breakthroughs for patients. The launch of the landmark CoMMpassSM Study, support in advancing six new myeloma therapies to market, and expansion in innovative academic/industry partnerships were among his numerous accomplishments. Prior to the MMRF, Walter had over 20 years of pharmaceutical and biotechnology leadership experience in Commercial Development, Operations, Finance, Marketing and Sales in the United States and internationally at Progenics Pharmaceuticals, Trimeris Inc., Triangle Pharmaceuticals, Bristol-Myers Squibb, Wyeth, Cyanamid Benelux and Lederle. In that time, he managed commercial drug product portfolios valued at over $500M; led or co-led the development, US and International launches as well as commercialization of 18 novel drugs including Fuzeon®, Emtriva®, Tequin®, Zerit®, Videx®, Maxipime® and Zosyn®; and managed over 30 other individual drug brands. Walter received his MBA from Columbia University Business School and BA from Brown University.

Dr. Milburn leads the company’s efforts to advance and expand its portfolio of Cancer Profilers to identify drug responders based on its proprietary Cancer Subtyping Platform (CSP®).  Prior to joining GeneCentric, Dr. Milburn was the CSO at Metabolon, leading the development and growth of the company’s successful research and development organization, which he joined in 2005 as one the first scientists recruited into the company.  In addition to overseeing R&D, he played an integral role in establishing high value scientific and commercial partnerships.   Prior to Metabolon, he served as Senior Vice President of Research and Corporate Development at Sirtris Pharmaceuticals and Senior Vice President of Research at Plexxikon.   He also held senior research positions at Structural Genomix (VP of Structural Biology); and GlaxoWellcome (Department Head of Structural Chemistry).  Dr. Milburn holds a BS in Chemistry (with highest honors) from the University of Michigan and a PhD in Biophysical Chemistry from the University of California at Berkeley.

Clay is an entrepreneur turned venture capitalist. Since 1995, Clay has co-founded seven companies in the life science arena and co-founded Hatteras in 2001. Since co-founding Hatteras, Clay has been instrumental in building the firm and has led investments in a range of life science companies, including biopharmaceutical, medical device, diagnostics, and research informatics.

Clay was the lead investor and led the strategic transaction process for ArtusLabs that resulted in its sale to PerkinElmer in 2011. He was a co-founder and served as CEO and Chairman of Synthematix, Inc., a chemistry informatics company that was acquired in April 2005 by Symyx Technologies (SMMX). Clay is a co-founder and former Chairman of PhaseBio Pharmaceuticals, Inc. He was the co-founder and head of corporate development for Novalon Pharmaceutical Corporation, where he led financing efforts and was head of business development from inception until Novalon’s sale to Karo Bio for $106.7 million in May of 2000. Prior to Novalon, Clay was the co-founder and president of Xanthon, Inc., a bioinformatics company with electro-chemical detection technology for direct analysis of DNA, RNA and proteins.

Clay currently serves as Chairman of GeneCentric Therapeutics and Lead Director of Pathfinder Therapeutics. He is also on the boards of PhaseBio Pharmaceuticals, Clearside Biomedical, and G1 Therapeutics. He also serves on the Board of Trustees of the NC Supplemental Retirement System and the NC BioFuels Center. He holds a Masters of Public Policy from Harvard University and a B.A. in mathematics and history from the University of North Carolina at Chapel Hill.

Dr. Lai-Goldman is the Chief Executive Officer and President of GeneCentric Therapeutics. She is also a founder and director of the Company. Dr. Lai-Goldman spent more than 18 years at Laboratory Corporation of America, Holdings (LabCorp), the last 10 years as Executive Vice President, Chief Medical Officer and Chief Scientific Officer. She served on LabCorp’s Executive and Management Committees, with strategic and operations responsibilities for 3 major genomic laboratories comprising more than 700 people. During her tenure at the Company, she led all clinical, scientific and medical activities, including the introduction of more than 400 clinical assays. Her experience includes the development of partnerships, licensing, and acquisitions. After leaving LabCorp, Dr. Lai-Goldman became a Venture Partner at Hatteras Venture Partners and is the managing partner of Personalized Science, LLC, a consulting company founded to assist customers achieve successful adoption of innovative diagnostics. Dr. Lai-Goldman received her BS from the University of Pennsylvania and MD from Columbia University College of Physicians and Surgeons. Dr. Lai-Goldman is Board-certified in anatomic and clinical pathology.

Ms. Ellen Lubman is a director of GeneCentric Therapeutics and Vice President of External Science and Innovation at Allergan, Inc. Ellen came to Allergan after joining predecessor company, Forest Laboratories, in February 2014 as Vice President, Strategy and Innovation Ellen’s mandate is to bring novel initiatives, products and opportunities to Allergan’s pipeline and increase the company’s access to scientific and structural innovation in defined areas of therapeutic expertise.

Ellen has 15+ years of experience throughout the biopharmaceutical industry. Ellen started her career as a pharmaceutical representative with Abbott Laboratories then joined investment banking firm, Robertson Stephens, as a Biotechnology equity research analyst during the height of the genomics revolution, focused on early stage drug discovery and development companies. After completing her MBA from Stanford Graduate School of Business with a focus on Global Management, Ellen joined as a founding member of a biotechnology private equity fund, Celtic Pharma. Ellen has worked with venture capital funds, seed-stage, biotech and pharma companies, in business and corporate development, operations and strategy roles, including Amgen, Kadmon Corporation and Bristol-Myers Squibb where she was instrumental in executing on the “String of Pearls” targeted growth strategy.

Dr. Levine has made significant contributions in the field of oncology in his research on the causes of cancer in both humans and animals. He was the first to discover the p53 tumour suppressor gene, which acts to protect individuals from developing cancer. Following his discovery, thousands of researchers have followed in Dr. Levine’s footsteps, seeking to focus on the p53 gene, which is the most commonly mutated gene in cancer.

Dr. Levine is currently a Professor at The Simons Center for Systems Biology at the Institute for Advanced Study in Princeton and a joint professor in the Pediatrics and Biochemistry Departments at the Cancer Institute of New Jersey. He received his PhD in microbiology from the University of Pennsylvania School of Medicine. Later he was a post-doctoral fellow of the Public Health Service at the California Institute of Technology.

Dr Levine also holds honorary degrees from, among other institutions, Rider University, the Weizmann Institute of Science, the University Pierre and Marie Curie in Paris and the University of Medicine and Dentistry of New Jersey. He has received many honours; most recently including the 2012 Onsager Medal, the Vallee Foundation Visiting Professorship, Harvard Medical School (2012), the Steven C. Beering Award for Advancement of Biomedical Science (2010), the American Cancer Society Medal of Honor (2009), the Kirk A. Landon-AACR Prize for Basic Cancer Research (2008), the Award for Basic Research from the Surgical Society of Oncologists (2003), the Albany Medical Center Prize in Medicine and Biomedical Research (2001), and the Medal for Outstanding Contributions to Biomedical Research from Memorial Sloan-Kettering Cancer Center (2000).

The May Goldman Shaw Distinguished Professor of Molecular Oncology
Professor of Genetics, and of Pathology & Laboratory Medicine
Member of the Lineberger Comprehensive Cancer Center
University of North Carolina at Chapel Hill

Dr. Perou’s research crosses the disciplines of genomics, cancer biology, bioinformatics, epidemiology, and clinical trials. Among the numerous, transformational advances led by Dr. Perou has been in the characterization of the genomic diversity of breast tumors, which resulted in the discovery of the Basal-like/Triple-Negative Breast Cancer subtype. He and his colleagues demonstrated that breast cancers can be classified into at least five molecular subtypes, with his lab focusing particular attention on the Basal-like subtype.  He is also elucidating the genetic causes that give rise to each subtype, modeling these events in Genetically Engineered Mouse Models, and then using these models to investigate tumor biology and the efficacy of new drugs and new drug combinations.

Dr. Perou has authored more than 330 peer reviewed articles, and is an inventor on multiple USA and European patents. He is the Faculty Director of the Lineberger Comprehensive Cancer Center (LCCC) Bioinformatics Group, and Co-Director of the LCCC Breast Cancer Research Program. He is a member of the ALLIANCE/CALGB Breast Committee, and Co-Chair of the Triple-Negative Working Group of the Translational Breast Cancer Research Consortium. In order to fulfill the vision of bringing genomic assays into the everyday cancer clinic to make improvements in personalized patient care, Dr. Perou co-founded Bioclassifier LLC, in addition to GeneCentric Therapeutics, Inc.

Dr. Perou earned his BA in Biology from Bates College, his PhD in Cell Biology from the University of Utah and completed his postdoctoral work in David Botstein’s laboratory while at Stanford University.  He joined the faculty at UNC in 2000 and has received numerous awards since including the 2009 AACR Outstanding Investigator Award for Breast Cancer Research, the 2011 Danaher Scientific and Medical Award, the 2012 European Institute of Oncology Breast Cancer Therapy Award, the 2013 Hyman L. Battle Distinguished Cancer Research Award from UNC, the 2016 Jill Rose Award for Distinguished Biomedical Research from the Breast Cancer Research Foundation, and the 2016 Brinker Award for Scientific Distinction from the Susan G. Komen. Lastly he has been named a Thomson Reuters Most Highly Cited Researcher in Clinical Medicine for 2014-16.

Scientific Director, University of Tennessee/West Institute for Cancer Research, and the Van Vleet Endowed Professor in Medical Oncology in the Department of Medicine (Division of Hematology‐Oncology).

Dr. Hayes’ research converges interests in multidisciplinary clinical care, clinical trials, translational cancer research, genomics, and model systems of cancer, with a focus on lung and head and neck cancers.  In the lab, he uses genetic and genomic techniques to characterize molecular alterations of cancer for the purposes of describing new patterns of clinically relevant disease and translating into includes biomarker discovery and validation.  Dr. Hayes currently is in his 10th year as a leader in efforts surrounding the Cancer Genome Atlas (TCGA), the pivotal genomic sequencing project of the decade.  His most notable accomplishments in this area include co‐leading the sequencing of RNA for most of the project, and playing a senior role in more than 20 manuscripts reported in Cell, Nature, and the New England Journal.

Early work by Dr. Hayes, performed in collaboration with his mentor Dr. Matthew Meyerson on human lung adenocarcinoma expression arrays from the National Cancer Institute revealed three reproducible molecular tumor subtypes of lung adenocarcinoma that are otherwise indistinguishable by routine clinical evaluation.  These subtypes possess statistically significant survival differences, independent of disease stage and are comprised of tumors with differing underlying rates of mutations in key lung cancer genes including KRAS and EGFR.  Similar findings for four subtypes of squamous cell carcinoma of the lung were also discovered and published.

Dr. Hayes most recently served as co‐leader of the University of North Carolina (UNC) Lineberger Clinical Research Program, professor in the Division of Hematology/Oncology and the Department of Otolaryngology/Head and Neck Cancer Surgery, and director of Clinical Bioinformatics at UNC.  Dr. Hayes lists more than 120 peer‐reviewed manuscripts in the last decade in the field of cancer research.  He received his BS from Davidson College, his MD from the University of North Carolina at Chapel Hill, his MPH from the Harvard School of Public Health and his MS from Tufts New England Medical Center. He completed his residency training in Internal Medicine at the Boston University School of Medicine, and additional fellowships in Hematology/Oncology at Tufts New England Medical Center and the Dana Farber Cancer Institute.

The May Goldman Shaw Distinguished Professor of Molecular Oncology
Professor of Genetics, and of Pathology & Laboratory Medicine
Member of the Lineberger Comprehensive Cancer Center
University of North Carolina at Chapel Hill

Dr. Perou’s research crosses the disciplines of genomics, cancer biology, bioinformatics, epidemiology, and clinical trials. Among the numerous, transformational advances led by Dr. Perou has been in the characterization of the genomic diversity of breast tumors, which resulted in the discovery of the Basal-like/Triple-Negative Breast Cancer subtype. He and his colleagues demonstrated that breast cancers can be classified into at least five molecular subtypes, with his lab focusing particular attention on the Basal-like subtype.  He is also elucidating the genetic causes that give rise to each subtype, modeling these events in Genetically Engineered Mouse Models, and then using these models to investigate tumor biology and the efficacy of new drugs and new drug combinations.

Dr. Perou has authored more than 330 peer reviewed articles, and is an inventor on multiple USA and European patents. He is the Faculty Director of the Lineberger Comprehensive Cancer Center (LCCC) Bioinformatics Group, and Co-Director of the LCCC Breast Cancer Research Program. He is a member of the ALLIANCE/CALGB Breast Committee, and Co-Chair of the Triple-Negative Working Group of the Translational Breast Cancer Research Consortium. In order to fulfill the vision of bringing genomic assays into the everyday cancer clinic to make improvements in personalized patient care, Dr. Perou co-founded Bioclassifier LLC, in addition to GeneCentric Therapeutics, Inc.

Dr. Perou earned his BA in Biology from Bates College, his PhD in Cell Biology from the University of Utah and completed his postdoctoral work in David Botstein’s laboratory while at Stanford University.  He joined the faculty at UNC in 2000 and has received numerous awards since including the 2009 AACR Outstanding Investigator Award for Breast Cancer Research, the 2011 Danaher Scientific and Medical Award, the 2012 European Institute of Oncology Breast Cancer Therapy Award, the 2013 Hyman L. Battle Distinguished Cancer Research Award from UNC, the 2016 Jill Rose Award for Distinguished Biomedical Research from the Breast Cancer Research Foundation, and the 2016 Brinker Award for Scientific Distinction from the Susan G. Komen. Lastly he has been named a Thomson Reuters Most Highly Cited Researcher in Clinical Medicine for 2014-16.

Dr. Lai-Goldman is the Chief Executive Officer and President of GeneCentric Therapeutics. She is also a founder and director of the Company. Dr. Lai-Goldman spent more than 18 years at Laboratory Corporation of America, Holdings (LabCorp), the last 10 years as Executive Vice President, Chief Medical Officer and Chief Scientific Officer. She served on LabCorp’s Executive and Management Committees, with strategic and operations responsibilities for 3 major genomic laboratories comprising more than 700 people. During her tenure at the Company, she led all clinical, scientific and medical activities, including the introduction of more than 400 clinical assays. Her experience includes the development of partnerships, licensing, and acquisitions. After leaving LabCorp, Dr. Lai-Goldman became a Venture Partner at Hatteras Venture Partners and is the managing partner of Personalized Science, LLC, a consulting company founded to assist customers achieve successful adoption of innovative diagnostics. Dr. Lai-Goldman received her BS from the University of Pennsylvania and MD from Columbia University College of Physicians and Surgeons. Dr. Lai-Goldman is Board-certified in anatomic and clinical pathology.

Hatteras Venture Partners is a venture capital firm that builds transformational companies in the areas of biopharmaceuticals, medical devices, diagnostics, healthcare IT, and related opportunities in human medicine. We typically invest in companies built on cutting-edge science from leading academic institutions. The firm has invested in companies across the United States in most of the major hotspots for health innovation. Given our headquarters location in RTP, NC, Hatteras plays a leadership role in building companies in North Carolina and the Southeastern United States, where technology is plentiful but resident venture capital is limited.

Learn More

Bristol-Myers Squibb is a differentiated company, led by our unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. We work every day to deliver innovative medicines for patients with serious and life-threatening diseases.

Each day, our employees around the world work together for patients – it drives everything we do. We are focused on helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunoscience and fibrosis. Through our R&D organization, we have built a sustainable pipeline of potential therapies, and actively partner to access external innovation to broaden and accelerate our work.

Learn More

LabCorp provides leading-edge medical laboratory tests and services through a national network of primary clinical laboratories and specialty testing laboratories.With scientific expertise in esoteric testing, genomics, and clinical and anatomic pathology, LabCorp processes tests on approximately 500,000 specimens each day, applying advances in medicine and science to laboratory testing.LabCorp operates a sophisticated laboratory network, with corporate headquarters in Burlington, NC, and more than 50,000 employees worldwide. Our 220,000 clients include physician offices, hospitals, managed care organizations, and biotechnology and pharmaceutical companies. Laboratory Corporation of America Holdings is listed on the New York Stock Exchange (NYSE) under ticker symbol LH.

Learn More